Baxter International Inc. (BAX) said immunoglobulin, a product derived from human plasma, failed to help patients with Alzheimer’s disease in a late-stage clinical trial, adding to a string of failures to develop a treatment for the most common form of dementia.
Current studies of immunoglobulin as a treatment for mild to moderate forms of the illness will be discontinued, and the company will reconsider its approach to its Alzheimer’s program, Deerfield, Illinois-based Baxter said in a statement today.
Immunoglobulin failed to reduce the cognitive decline or preserve functional abilities in Alzheimer’s patients after 18 months of treatment, the company said.
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH9jlh7cJjnO4EHak04HMq-H5lM1Q&url=http://www.bloomberg.com/news/2013-05-07/baxter-immunoglobulin-fails-to-aid-alzheimer-s-patients.html
0 comments:
Post a Comment